I did this introductory course on managing and commercialising current innovations in BioTechnology in 2010. *This project preceded development in depth technology strategies coronary stent innovations.

1. Avatar Coronary Stents
Liang Kun (CEO)
Yeong Poh Sheng (CTO)
Choo Jun Quan (CMO)
Chong Mun Keat (CFO)
“To provide high quality, affordable cardiac intervention and treatment
devices for the South-East Asian community.”
Avatar Medical Pte Ltd.

2. Board of
Director
CEO
Product
Development (CTO)
Distribution,
Marketing (CMO)
Finance (CFO) Corporate Affairs
Business
Development
(Advisory Board)

3. Market Research

4. Why Coronary Artery Disease
The leading cause of death worldwide: 12.2%
7.2 million annual worldwide deaths in 2004, estimated to reach 11.1 million by 2020
Poses significant social-economic burden
WHO: Will keep this trend toward 2030 at least……….

5. FYI about CAD
• Blockage in the coronary artery (High BP & Cholestrol, diabetes etc)
• Block the blood and oxygen supply to HEART
• HEART “CHOKE”: infarction
• HEART ATTACK!!!

6. Why Coronary Stent
• Bypass (Unnecessary)
• Angioplasty PCI
• BMS/DES
• Transplant (Chronic)

7. Dilemma!!!
• BMS
 Gradually out for
competition
 CHEAPER
• DES
 Restenosis
 late stent thrombosis
 Dual Anti-Platelet Therapy
Death, Stroke or Myocardial Infarction

8. A New Generation STENT
Asia- The world Fastest Growing market of
Coronary Artery( 2008:$2,000,000,000 ++)

9. Why Indonesia
• the 1st mortality and morbidity in Indonesia (14%) since 2002
• 4th most populated country in the world (238,000,000)
• One of the highest population growth rates
• Strategic location
• SEA market is underdeveloped
• No patent issues on drugs we use
Indonesia’s medical device market- US$409
million in 2009.

10. Our Products
Cobalt-Chromium Bare
Metal Stent ( CoCr BMS)
Polymer Coated Dual-
Drug Eluting Stent
(PCDES)

11. Cobalt-Chromium Bare Metal
Stent
• Quality Product - Thin, flexible and
strong stent with proven clinical
efficacy. (CE Mark)
• Excellent Properties – Low recoil,
low tissue reactivity, excellent
deliverability
• Competitive Pricing - $500 (Selling
prices to distributors)
1. 2009 Insightra Medical, Inc. USA.
CoCr BMS

12. Polymer Coated Dual-Drug
Eluting Stent
PCDES
1. S. Venkatraman and F. Boey, Release profiles in drug-eluting stents: issues and uncertainties, J Control Release 120 (2007), pp. 149–160
2. Y Huang, SS Venkatraman, FYC Boey, EM Lahti, PR Umashankar, M Mohanty, S Arumugam, L Khanolkar, S Vaishnav, In vitro and in vivo
performance of dual drug-eluting stent (DDES), Biomaterials 31 (2010) 4382-4391
• Coated with both Sirolimus (antiproliferative
drug for restenosis) and Triflusal (anti-clotting
drug for thrombosis in PLGA polymer layer
• Release of drugs controlled by PLGA
degradation
• Preliminary in vivo studies demonstrated
restenosis reduction
• Product in clinical trials (projected to be
available in market in 3-5 years)

13. Existing Drug Eluting Stents
(DES)
CYPHER DES BIOMATRIX DES
XIENCE V DES

14. Competitive Advantages
PCDES
• Targets both Restenosis and Thrombosis
by having Two Drugs
• Addresses long term complications by
controlled release of two drugs
• Possibly eliminate Dual Anti-Platelet
Therapy (DAPT)

15. Next Generation
Bioabsorbable Stents
Abbott Bioabsorbable
Vascular Solutions Stent
(BVS)
Biotronik Absorbable
Magnesium Stent (AMS)

16. Name of
Stent
Manufacturer Stent Platform Coating Material,
(Duration of
Biodegradation,
Months)
Drug/s (Dosage) Release Rate
(%). Time
(days)
Indicators
(MACE, thrombosis,
restenosis)
Remarks Estimated
Price
(USD)
CYPHER Cordis Stainless Steel Permanent
Polymer, (PEVA
amd PBMA)
Sirolimus**
(140ug/cm2)
80%, 30 12.2%MACE, at least
12% restenosis,
thrombosis average 0.8%
within 6 year
Aspirin,
Clopidogrel
treatment needed
$2700
Biomatrix Biosensor Stainless Steel Poly-L-lactic Acid
(6-9)
Biolimus A9
(15.6ug/mm2)
45%, 30 10.7% MACE, 3.9%-
5.5% restenosis, 0%
thrombosis within 1 year
Aspirin,
Clopidogrel
treatment needed
$3000
Xience V Abbott Cobalt
Chromium
Permanent
Polymer, (PVDF-
HFP)
Everolimus
(100ug/cm2)
80%, 28 4.6% MACE, 2.3% in-
stent Restenosis and 0.5%
thrombosis at 9 months
Aspirin,
Clopidogrel
treatment needed
$2600
AMS Biotronik Magnesium - - - No MACE, thrombosis at
2 years, no cases of in
stent restenosis, low
neointimal hyperplasia.
Aspirin,
Clopidogrel
treatment needed
Not on
Market
BVS Abbott Poly-L-lactic
Acid
Poly-D-Lactic
Acid
Everolimus
(variable)
80%, 30 No MACE, thrombosis at
12 months, 47% in stent
restenosis at 4 months,
45% need
revascularizations
Aspirin,
Clopidogrel
treatment needed
Not on
Market
PCDES* - Cobalt-
Chromium
PLGA (Poly (D,L-
Lactic-co-
Glycolic acid))
Sirolimus +
Triflusal
(variable)
Si: 70%, 30
Tri: 99%, 5
Reduction in stenosis as
compared to BMS (30%
to 22%), Neointimal Area
(1.71mm2 to 1.23mm2)
Not tested. $2500
(Projected)

17. Bare-
Metal
Stents
Drug-
Eluting
Stent (DES)
Bio-
absorbable
Drug-
Eluting
Stent
Polymer
Coated
Dual-Drug
Eluting
Stent
Reduce
Restenosis
Reduce Risk
of Thrombosis
Freedom from
DAPT
Controllable
Drug Release

18. Strategy, a word of military origin, refers to a plan of
action designed to achieve a particular goal

19. Business & Marketing Strategies
Hospitals
•Seamless medical
application engineers and
technical support.
Distributors
•Prioritized distribution of
Avatar’s Co-Cr stents
through 10%
Shareholder’s Equity
•% of sales force is
dedicated to promoting
Avatar Co-Cr Stents.
US
•Import Co-Cr Stents- India to
Indonesia (Initial Phase: 9 mths-
1½ years)
• Evaluate Contract Manufacturing
with Kalbe Farma’s partners. (1
½ to 4 years)
• Compliance with ISO13485/
ISO9001 for manufacturing
standards
•Establish local manufacturing
facilities in Indonesia for DES
(After 1st 4 years)
•Hold annual technology- based
conferences.
•Bi- Monthly Trg seminars- Major
Cities
• License Co-Cr Stents from Prof.
Freddy Boey (C.E. Mark Certified).
•Joint- Collaboration with distribution
companies to product, distribute
maximize market penetration.
 Reduced time to market
 Reduced costs to market
Interconnected framework for success
• IP Protection for DDES-
•Filing of Patent
PCT/SG2004/000180-
(Venkatraman, FYC Boey,
Polymeric Stent and Method of
Manufacture ) in Indonesia- 3rd
Year
• Setting up manufacturing facilities in
Indonesia
Low cost workforce
• Research and Operations Base in
Singapore
Leverage Singapore’s position as
a Biotechnology and Trade Hub for
research and collaborations.

20. Customer
Segmentation
Framework
•I
Java
58%
Other Areas
42%
Population Distribution in
Indonesia
Java, 531
Sumatra, 277
Sulawesi, 112
Kalimantan,
84
Maluku and
Irian Jaya,
42 others, 65
Hospital Segmentation in
Indonesia
Population and Hospital
Distribution in Indonesia
Mass Market
Segment
Upmarket
Segment
Financially
Impeded
Market
•5% of Major Cities- Jakarta &
Surabaya
•Rich prefers quality
treatment overseas-
Malaysia and Singapore.

21. Year 1 Year 2 Year 3 Year 4 Year 5
Investment: $4.5 millions
-
2,000,000.00
4,000,000.00
6,000,000.00
8,000,000.00
10,000,000.00
12,000,000.00
14,000,000.00
1 2 3 4 5
Revenue/US$
year
Forecast Sale
How much can we earn?

22. 238,000,000
330,000
167,000
12,128
3,032

23. 1. Indonesia population 238,000,000
2. Number of patients 330,000
Max Potential Intervention of
Coronary Stents (49%) 161,700
1st year % 2nd year % 3rd year % 4th year % 5th year %
3. Projected hospitals 40,425 25 52,553 33 88,935 55 113,190 70 113,190 70
4.
Mid-upper income families afford to
pay for the operation
12,128
30 15,766 30 26,681 30 33,957 30 33,957 30
5. Doctors opt for our coronary stents 3,032 25 5,518 35 12,006 45 22,072 65 23,770 70
1,515,937.50 2,759,006.25 6,003,112.50 11,036,025.00 11,884,950.00
0.02 0.03 0.07 0.14 0.15
151,593.75 275,900.63 600,311.25 1,103,602.50 1,188,495.00
Revenue/US$ (US$500/bare metal stent)
Quantity (cases)
$11,884,950
Projected Revenue

24. Revenue 1st year/ US$'000 2ndyear/ US$'000 3rdyear/ US$'000 4th year/ US$'000 5th year/ US$'000
Product revenue 1,516 2,759 6,003 11,036 11,885
Cost of Sales (152) (276) (600) (1,104) (1,188)
Gross profit 1,364 2,483 5,403 9,932 10,696
Operating expenses
Selling, Generaland Administrative Expenses (1,868) (1,003) (1,019) (1,049) (1,068)
Research and development expenses (76) (193) (100) (100) (100)
Other operating expenses (45) (28) (500) (500) (250)
Contingency expenses (20% of gross expenses) (398) (245) (324) (330) (284)
Subtotal (2,387) (1,469) (1,619) (1,649) (1,701)
Profit/ (Loss) before taxation (1,023) 1,014 3,784 8,283 8,995
Taxation - (304) (1,135) (2,485) (2,699)
Net Profit for the year (1,023) 710 2,649 5,798 6,297
Projected Net Profit

25. (2,000,000)
-
2,000,000
4,000,000
6,000,000
8,000,000
10,000,000
12,000,000
14,000,000
1 2 3 4 5
US$
Year
Projected Revenue and Net Profit
Profit
Revenue
$6,297,000
$4.5 millions investment

27. Summary
“To provide high quality, affordable cardiac intervention and treatment
devices for the South-East Asian community.”
Avatar Medical Pte Ltd.
•Large market with potential for exponential growth
•Quality, affordable and innovative products to
improve the current coronary intervention therapy
•Proven customer centric, cost effective business
model
•Interconnected framework of global talent for
success

28. Formula for A
Successful Business Partnership
Technical
Knowledge and
Business
Strategies
Execution
High Quality,
Co- Cr Stents
DDES
Funding &
Infrastructure
Ambitious
Global Outlook